Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Int J Biol Macromol. 2024 Aug 14:134779. doi: 10.1016/j.ijbiomac.2024.134779. Online ahead of print.
ABSTRACT
Excessive iron in the liver may exacerbate Non-alcoholic fatty liver disease (NAFLD) by increasing the risk of liver cell expansion, inflammation and fibrosis. Ferroptosis in liver cells may lead the progression of simple fatty liver degeneration to steatohepatitis (NASH). More and more studies shew that ferroptosis played a crucial role in the pathological process of NAFLD. Based on the mechanism of ferroptosis, this study first synthesized a liver targeted 18-β-Glycyrrhetinic-acid-chitosan oligosaccharide -N-acetylcysteine polymer (GCNp), and further curcumin (Cur) was used as model drug to prepare Cur loaded nanodelivery system (GCNp-Cur NPs). The particle size of GCNp-Cur NPs was 132.5 ± 9.8 nm, PDI was 0.148 ± 0.026 and the potential was 23.8 mV. GCNp-Cur NPs can regulate the GPX4/GSH pathway, inhibit lipid peroxidation, restore cellular oxidative environment, reduce free Fe2+, improve cellular lipid metabolism and iron metabolism, thereby NPs inhibited liver cell ferroptosis through multiple pathways. Additionally, GCNp-Cur NPs could also alleviate liver tissue lipid accumulation and oxidative damage, delaying disease progression, and providing a new method and theoretical basis for the treatment of NAFLD.
PMID:39151850 | DOI:10.1016/j.ijbiomac.2024.134779
![Google](https://www.google.com/images/branding/googlelogo/2x/googlelogo_light_color_92x30dp.png)
![Google Keep](https://www.gstatic.com/images/branding/product/1x/keep_48dp.png)
![Share on Linkedin](https://psychiatryai.com/wp-content/uploads/2023/10/linkedin-logo-png-2048-1.png)
Estimated reading time: 4 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Cool Evidence: Engaging Young People and Students in Real-World Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Real-Time Evidence Search [Psychiatry]
![](/wp-content/uploads/2024/04/pubmed.png)
AI Research
![](/wp-content/uploads/2024/05/Il5nR_nf_400x400-modified-1.png)
GA receptor targeted chitosan oligosaccharide polymer nanoparticles improve non-alcoholic fatty liver disease by inhibiting ferroptosis
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury Silica nanoparticles induce liver lipid metabolism disorder via ACSL4-mediated ferroptosis Unveiling the role of ferroptosis in the progression from NAFLD to NASH: recent advances in mechanistic understanding Association between nonalcoholic steatohepatitis and high serum ferritin levels in type 2 diabetes mellitus Bioinformatics analysis of potential ferroptosis and non-alcoholic fatty liver disease biomarkers Bioinformatics analysis of potential ferroptosis and non-alcoholic fatty liver disease biomarkers Liver Fatty Acid-binding Protein Is a More Reliable Biomarker for Liver Injury in Nonalcoholic Steatohepatitis than Other Etiologies of Hepatitis Haloacetamides disinfection by-products, a potential risk factor for nonalcoholic fatty liver disease A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact RNA modifications in the progression of liver diseases: from fatty liver to cancer RNA modifications in the progression of liver diseases: from fatty liver to cancer Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice The role and mechanism of SUMO modification in liver disease Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies Single-Cell Data Analysis Reveals Critical Hepatic Cells Subpopulations in the Progression of Non-alcoholic Fatty Liver Disease to Non-Alcoholic Steatohepatitis Decrease in UCP1 by sustained high lipid promotes NK cell necroptosis to exacerbate nonalcoholic liver fibrosis Hericium erinaceus polysaccharides ameliorate nonalcoholic fatty liver disease via gut microbiota and tryptophan metabolism regulation in an aged laying hen model Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes Roflumilast ameliorates GAN diet-induced non-alcoholic fatty liver disease by reducing hepatic steatosis and fibrosis in ob/ob mice The Beneficial Effect of Brazilian Propolis for Liver Damage through Endoplasmic Reticulum Stress Mast cells and the gut-liver Axis: Implications for liver disease progression and therapy Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease Alantolactone attenuates high-fat diet-induced inflammation and oxidative stress in non-alcoholic fatty liver disease Ferroptosis in health and disease The rs1862513 promoter variant of resistin gene influences susceptibility to nonalcoholic fatty liver disease The Transition in Terminology: From Non-alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD) to Metabolic-associated Steatotic Liver Disease (MASLD) Navigating the Link Between Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis and Cardiometabolic Syndrome Impact of lifestyle interventions on pathogenesis of nonalcoholic fatty liver disease Gentiopicroside improves NASH and liver fibrosis by suppressing TLR4 and NLRP3 signaling pathways Near-infrared lipid droplets polarity fluorescent probe for early diagnosis of nonalcoholic fatty liver disease Exploring Fibrosis Pathophysiology in Lean and Obese Metabolic-Associated Fatty Liver Disease: An In-Depth Comparison Serum miR‑29 is increased in mice with early liver fibrosis Exerkines: Benign adaptation for exercise and benefits for non-alcoholic fatty liver disease Hepatic miR-363 promotes non-alcoholic fatty liver disease by suppressing INSIG1 Paricalcitol attenuates oxidative stress and inflammatory response in the liver of NAFLD rats by regulating FOXO3a and NFκB acetylation Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review Relationship between Neutrophil-to-Lymphocyte Ratio and Liver Fibrosis in Nonalcoholic Fatty Liver Disease Among Adults in the United States: Data from the National Health and Nutrition Examination Survey 2017-2018 The role and mechanism of pyroptosis and potential therapeutic targets in non-alcoholic fatty liver disease (NAFLD) Discovery of genomic loci for liver health and steatosis reveals overlap with glutathione redox genetics The Flavonoid Glycoside from Abrus cantoniensis Hance Alleviates Alcoholic Liver Injury by Inhibiting Ferroptosis in an AMPK-Dependent Manner Prevalence and Association of Risk Factors According to Liver Steatosis and Fibrosis Stages among Nonalcoholic Fatty Liver Disease Patients with Type 2 Diabetes Mellitus in India: A Cross-sectional Study Current and experimental pharmacotherapy for the management of non-alcoholic fatty liver disease Progress of mesenchymal stem cells (MSCs) & MSC-Exosomes combined with drugs intervention in liver fibrosis Influence of nonalcoholic fatty liver disease severity on carotid adventitial vasa vasorum Efficacy and mechanism of action of Yanxiao Di'naer formula for non-alcoholic steatohepatitis treatment based on metabolomics and RNA sequencing Efficacy and mechanism of action of Yanxiao Di'naer formula for non-alcoholic steatohepatitis treatment based on metabolomics and RNA sequencing Complex dichotomous links of nonalcoholic fatty liver disease and inflammatory bowel disease: exploring risks, mechanisms, and management modalities Asprosin aggravates nonalcoholic fatty liver disease via inflammation and lipid metabolic disturbance mediated by reactive oxygen species Hepatic lipopolysaccharide binding protein partially uncouples inflammation from fibrosis in MAFLD Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation Targeting chronic liver diseases: Molecular markers, drug delivery strategies and future perspectives From non-alcoholic fatty liver disease to metabolic-associated steatotic liver disease: Rationale and implications for the new terminology Depletion of Activated Hepatic Stellate Cells and Capillarized Liver Sinusoidal Endothelial Cells Using a Rationally Designed Protein for Nonalcoholic Steatohepatitis and Alcoholic Hepatitis Treatment FGL1 and FGL2: emerging regulators of liver health and disease The Pan Immune Inflammatory Value in Relation to Non-Alcoholic Fatty Liver Disease and Hepatic Fibrosis Medaka liver developed Human NAFLD-NASH transcriptional signatures in response to ancestral bisphenol A exposure The association between endocrine disrupting chemicals and nonalcoholic fatty liver disease: A systematic review and meta-analysis A PNPLA3-Deficient iPSC-Derived Hepatocyte Screen Identifies Pathways to Potentially Reduce Steatosis in Metabolic Dysfunction-Associated Fatty Liver Disease EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)
Evidence Blueprint
GA receptor targeted chitosan oligosaccharide polymer nanoparticles improve non-alcoholic fatty liver disease by inhibiting ferroptosis
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
GA receptor targeted chitosan oligosaccharide polymer nanoparticles improve non-alcoholic fatty liver disease by inhibiting ferroptosis
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
Iron metabolism and ferroptosis in Non-alcoholic fatty liver disease: what is our next step? Multiscale 3D genome organization underlies duck fatty liver with no adipose inflammation or serious injury Research progress on the mechanism of action of heme oxygenase-1 regulating ferroptosis in non-alcoholic fatty liver disease Silica nanoparticles induce liver lipid metabolism disorder via ACSL4-mediated ferroptosis Depletion of Igfbp7 alleviates zebrafish NAFLD progression through inhibiting hepatic ferroptosis Selective autophagy associated with iron overload aggravates non-alcoholic steatohepatitis via ferroptosis Unveiling the role of ferroptosis in the progression from NAFLD to NASH: recent advances in mechanistic understanding Association between nonalcoholic steatohepatitis and high serum ferritin levels in type 2 diabetes mellitus Identification of hyperoxidized PRDX3 as a ferroptosis marker reveals ferroptotic damage in chronic liver diseases The Influence of Emodin Succinyl Ethyl Ester on Non-Alcoholic Steatohepatitis Induced by a Diet High in Fructose, Cholesterol, and Fat in Mice Bioinformatics analysis of potential ferroptosis and non-alcoholic fatty liver disease biomarkers Bioinformatics analysis of potential ferroptosis and non-alcoholic fatty liver disease biomarkers Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis Melatonin targets ferroptosis through bimodal alteration of redox environment and cellular pathways in NAFLD model Overexpression of Interleukin-8 Promotes the Progression of Fatty Liver to Nonalcoholic Steatohepatitis in Mice Therapeutic effect of long-acting FGF21 with controlled site-specific modification on nonalcoholic steatohepatitis Atorvastatin on Treatment of Nonalcoholic Fatty Liver Disease Patients Effect of the nomenclature of non-alcoholic fatty liver disease on diagnosis and treatment of fatty liver disease concomitant with other liver diseases Pathophysiological Features of Rat Models of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis Tanshinone _A inhibits ferroptosis via Nrf2 signaling pathway to protect liver in rats of non-alcoholic fatty liver disease Autophagy and the unfolded protein response shape the non-alcoholic fatty liver landscape: decoding the labyrinth Liver Fatty Acid-binding Protein Is a More Reliable Biomarker for Liver Injury in Nonalcoholic Steatohepatitis than Other Etiologies of Hepatitis The role of Sirtuin 2 in liver - An extensive and complex biological process Metabolic study of iron deposition based on magnetic resonance in patients with nonalcoholic fatty liver disease Metformin alleviates hepatic iron overload and ferroptosis through AMPK-ferroportin pathway in HFD-induced NAFLD Immunomodulation in non-alcoholic fatty liver disease: exploring mechanisms and applications What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver? What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver? Non-alcoholic fatty liver disease and periodontal disease: A systematic review and meta-analysis of cross-sectional studies Liver fibrosis screening, evaluation pathway, and management in patients with fatty liver Haloacetamides disinfection by-products, a potential risk factor for nonalcoholic fatty liver disease Polysaccharide from Panax japonicus C.A. Mey prevents non-alcoholic fatty liver disease development based on regulating liver metabolism and gut microbiota in mice Ferroptosis contributes to ethanol-induced hepatic cell death via labile iron accumulation and GPx4 inactivation Targeted platelet with hydrogen peroxide responsive behavior for non-alcoholic steatohepatitis detection Gypenoside XIII regulates lipid metabolism in HepG2 hepatocytes and ameliorates nonalcoholic steatohepatitis in mice A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice Role of gut microbiota and immune cells in metabolic-associated fatty liver disease: clinical impact From NAFLD to NASH: Understanding the spectrum of non-alcoholic liver diseases and their consequences Bioinformatics analysis of ferroptosis-related genes and immune cell infiltration in non-alcoholic fatty liver disease Role of microRNA in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a comprehensive review A Systematic Review of Statins for the Treatment of Nonalcoholic Steatohepatitis: Safety, Efficacy, and Mechanism of Action RNA modifications in the progression of liver diseases: from fatty liver to cancer RNA modifications in the progression of liver diseases: from fatty liver to cancer SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice SHMT2 reduces fatty liver but is necessary for liver inflammation and fibrosis in mice Chiglitazar attenuates high-fat diet-induced nonalcoholic fatty liver disease by modulating multiple pathways in mice The role and mechanism of SUMO modification in liver disease Isolation, purification, and structural characterization of polysaccharides from Codonopsis pilosula and its therapeutic effects on non-alcoholic fatty liver disease in vitro and in vivo Global perspective on nonalcoholic fatty liver disease and nonalcoholic steatohepatitis - prevalence, clinical impact, economic implications and management strategies Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease The gut-liver axis in fatty liver disease: role played by natural products FMO2 ameliorates nonalcoholic fatty liver disease by suppressing ER-to-Golgi transport of SREBP1 Vitamin D/Vitamin D receptor pathway in nonalcoholic fatty liver disease Single-Cell Data Analysis Reveals Critical Hepatic Cells Subpopulations in the Progression of Non-alcoholic Fatty Liver Disease to Non-Alcoholic Steatohepatitis Decrease in UCP1 by sustained high lipid promotes NK cell necroptosis to exacerbate nonalcoholic liver fibrosis Medium- and long-chain triglyceride propofol activates PI3K/AKT pathway and inhibits non-alcoholic fatty liver disease by inhibiting lipid accumulation Fatty liver disease's renaming impacts on drug clinical trials Non-alcoholic fatty liver disease promotes liver metastasis of colorectal cancer via fatty acid synthase dependent EGFR palmitoylation Recent Advances in Mesenchymal Stem/Stromal Cell-Based Therapy for Alcohol-Associated Liver Disease and Non-alcoholic Fatty Liver Disease Fatty liver is associated with significant liver inflammation and increases the burden of advanced fibrosis in chronic HBV infection Role of FXR in the development of NAFLD and intervention strategies of small molecules Hericium erinaceus polysaccharides ameliorate nonalcoholic fatty liver disease via gut microbiota and tryptophan metabolism regulation in an aged laying hen model Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes Immune system dysregulation in the pathogenesis of non-alcoholic steatohepatitis: unveiling the critical role of T and B lymphocytes